Business Context and Reporting Period
Syndax Pharmaceuticals Inc. (SNDX) filed a Form 8-K on January 12, 2026, to disclose preliminary financial results presented at the 44th Annual J.P. Morgan Healthcare Conference. The data covers the fiscal year ended December 31, 2025, and the fourth quarter of that year.
Key Financial Metrics
| Metric | Q4 2025 (Preliminary) | Full Year 2025 (Preliminary) |
|---|---|---|
| Revuforj (revumenib) U.S. Net Product Revenue | $44 million | $125 million |
| Niktimvo (axatilimab-csfr) U.S. Net Product Revenue | $56 million | $152 million |
| Total Cash, Cash Equivalents, and Marketable Securities | $394 million (as of Dec 31, 2025) |
Note: The filing does not provide consolidated total revenue, net profit, operating margins, or debt figures. The Company stated it will report its share of net commercial profit for Niktimvo when full-year 2025 results are announced.
Material Changes and Outlook
The filing provides preliminary revenue figures for two key products but does not explicitly state percentage changes versus the prior comparable period. Management indicated that the audit for the year ended December 31, 2025, is ongoing, and final results may differ from these preliminary approximations. Complete financial results are expected to be announced in early 2026.
Investor Verification Checklist
- Verify the final audited revenue figures for Revuforj and Niktimvo against these preliminary estimates when the full-year 2025 report is released.
- Confirm the Company's share of net commercial profit for Niktimvo, which was not disclosed in this filing.
- Review the upcoming full-year report for consolidated net income, operating expenses, and cash flow statements, which are absent here.
- Monitor for any adjustments to the $394 million cash position resulting from the ongoing audit.